[go: up one dir, main page]

CN101301384A - Chinese medicinal composition for treating arteriosclerosis - Google Patents

Chinese medicinal composition for treating arteriosclerosis Download PDF

Info

Publication number
CN101301384A
CN101301384A CNA2008100169692A CN200810016969A CN101301384A CN 101301384 A CN101301384 A CN 101301384A CN A2008100169692 A CNA2008100169692 A CN A2008100169692A CN 200810016969 A CN200810016969 A CN 200810016969A CN 101301384 A CN101301384 A CN 101301384A
Authority
CN
China
Prior art keywords
grams
radix
medicine
treating arteriosclerosis
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008100169692A
Other languages
Chinese (zh)
Inventor
刘昌州
田玉亭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNA2008100169692A priority Critical patent/CN101301384A/en
Publication of CN101301384A publication Critical patent/CN101301384A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a medicine, particularly relating to a Chinese medicine composition for treating arteriosclerosis. The Chinese medicine composition for treating arteriosclerosis is characterized in that the mass portions of the components are: 1 to 2 grams of mint, 1 to 2 grams of chrysanthemum, 1 to 2 grams of cimicifuga foetida, 1 to 2 grams of bark of tree peony root, 1 to 2 grams of rhubarb, 1 to 2 grams of euphorbia kansui, 1 to 2 grams of common andrographis herb, 1 to 2 grams of asiatic plantain seed, 1 to 2 grams of akebia stem, 2 to 4 grams of orange peel, 2 to 4 grams of cyrtomium rhizome, 2 to 4 grams of baical skullcap root, 2 to 4 grams of abalone shell, 2 to 4 grams of safflower, 2 to 4 grams of salvia, 2 to 4 grams of earthworm, 2 to 4 grams of frankincense and 2 to 4 grams of jasper powder. The medicine of the invention is safe, effective and good in tolerance, so that the medicine can be routinely prescribed to treat a patient with carotid atherosclerosis and prevent cardiocerebrovascular events and has the advantages of safety and reliability, obvious curative effect, small side effect and high cure rate.

Description

The arteriosclerotic Chinese medicine composition of a kind of treatment
(1) technical field
The present invention relates to a kind of medicine, the arteriosclerotic Chinese medicine composition of particularly a kind of treatment.
(2) background technology
Arteriosclerosis is a kind of non-inflammation pathological changes of tremulous pulse, can make that ductus arteriosus wall thickens, hardening, follow the string and tube chamber narrow and small.The arteries and veins sclerosis has three kinds of main types: (1) tiny arteriosclerosis; (2) medial arteriosclerosis; (3) atherosclerosis.Arteriosclerosis is that its rule normally takes place at adolescence along with people's age increases and the angiopathy that occurs, increases the weight of period, falls ill to person in middle and old age.The male is many than the women, and primary disease increases gradually in China in recent years, becomes one of old people's main cause of death.The most important thing is hypertension, hyperlipidemia, smoking three big risk factor in the arteriosclerotic reason.Other obesities, diabetes, hypomotility, tense situation, advanced age, family's medical history, short-tempered etc. relation arranged all.Atherosclerotic performance depends mainly on vascular lesion and the degree of ischemia of the organ of getting involved, and for early stage arteriosclerosis patient, Most patients all is in the development of hiding under the hidden evil thoughts state nearly all without any clinical symptoms.Arteriosclerosis patient for mid-term, clinical symptoms such as all more or less had palpitation, nervous, chest pain, uncomfortable in chest, headaches of Most patients, dizziness, the cool fiber crops of extremity, extremity are listless and aching, limping, vision reduction, hypomnesis, insomnia, dreaminess, different patients has different symptoms.
The contingent complication of arteriosclerosis: coronary atherosclerosis person, if caliber is narrow to be reached more than 75%, then angina pectoris, myocardial infarction, arrhythmia can take place, even sudden death.Cerebral arteriosclerosis can cause cerebral ischemia (comprising transient ischemic attack (TIA)), brain atrophy, or cause rupture of blood vessel in brain hemorrhage.The commitment of cerebral arteriosclerosis: the neurasthenia (often has dizziness, giddy, headache, tinnitus, drowsiness, hypomnesis, fatiguability), (emotion is emotional, lacks possessiveness unusually for emotion, along with increasing the weight of of the state of an illness, the apathetic expression that can become gradually lacks interest to surrounding), judgement low (show as can not hold and focus one's attention on, imaginative power reduces, and handling problem will lean on others to assist).Stiff or the walking shakiness of gait can appear when cerebral arteriosclerosis reaches middle and late stage, dementia, epileptic convulsion, apoplexy.Renal artery is atherosis, often causes that frequent urination at night, intractable hypertension, severe patient can have renal insufficiency.Superior mesenteric atherosclerosis can show as after the heavy meal stomachache symptom such as have blood in stool.Artery of lower extremity is atherosis, and early symptom mainly shows as intermittent claudication, and the performance that pain then is severe lower extremity ischemia also takes place during rest, and often with acroanesthesia, dorsal artery of foot is beaten and disappeared etc.Acra ulcer and gangrene also can take place in late period.
Nothing is specially controlled arteriosclerotic specific drug at present.
(3) summary of the invention
The present invention provides a kind of treatment evident in efficacy arteriosclerotic Chinese medicine composition in order to remedy the deficiencies in the prior art
The present invention is achieved through the following technical solutions:
The arteriosclerotic Chinese medicine composition of a kind of treatment, its special character is: the raw material by following parts by weight is made:
Herba Menthae 1-2g, Flos Chrysanthemi 1-2g, Rhizoma Cimicifugae 1-2g, Cortex Moutan 1-2g, Radix Et Rhizoma Rhei 1-2g, Radix Kansui 1-2g, Herba Andrographis 1-2g, Semen Plantaginis 1-2g, Caulis Akebiae 1-2g, Pericarpium Citri Reticulatae 2-4g, Rhizoma Osmundae 2-4g, Radix Scutellariae 2-4g, Concha Haliotidis 2-4g, Flos Carthami 2-4g, Radix Salviae Miltiorrhizae 2-4g, Pheretima 2-4g, Olibanum 2-4g, BIYUSAN 2-4g.
The arteriosclerotic Chinese medicine composition of treatment of the present invention, described medicine are water decoction, granule or capsule.
Below for the observation of curative effect of medicine of the present invention:
1 object and method
1.1 case selects to select at random in March, 2002 ~ 2005, here inpatient 100 examples in year March.The patient is many to go to a doctor with hypertension, type 2 diabetes mellitus, coronary heart disease, cerebral infarction, all has carotid artery intima middle level in various degree to thicken through the color Doppler inspection, and the speckle that has that has forms.At random 100 routine patients are divided into 2 groups.50 examples are organized in treatment, male 38 examples, women 12 examples, 68.7 years old mean age, hypertension 26 examples wherein, type 2 diabetes mellitus 11 examples, cerebral infarction 124 examples, coronary heart disease 23 examples, wherein dyslipidemia 43 examples; Matched group 50 examples, male 42 examples, women 8 examples, 67.6 years old mean age, hypertension 28 examples wherein, type 2 diabetes mellitus 5 examples, cerebral infarction 17 examples, coronary heart disease 16 examples, wherein dyslipidemia 47 examples.
Treatment and observational technique
1.2.1 dietary habit, life style and the accompanying diseases used medicine of two groups of patients during treating all with before the treatment is consistent.Make patient's blood pressure, blood glucose up to standard as far as possible.The treatment group is used medicine every day twice of the embodiment of the invention 1, and each 1 gram is taken before sleeping; Matched group uses placebo, one day 2 times, 5 months courses of treatment.
1.2.2 two groups of common carotid artery structure 100 routine patients all adopt Color doppler ultrasound patient bilateral carotid arteries before and after treatment.The patient gets dorsal position, the shoulder bed hedgehopping, and the neck layback fully exposes cervical region.Measurement to the total endarterium of cervical region-middle level thickness (IMT): show the clearest place's measurement tube wall IMT in the common carotid artery structure, measure 3 times, average normal value≤0.9mm.Arterial wall thickens and is defined as: local I MT 〉=1.0mm, and≤1.2mm.Atheromatous plaque is defined as: local I MT>1.2.The measurement of speckle determines that with two peacekeeping color Dopplers speckle exists, and measures the maximum ga(u)ge (Tmax) of speckle on longitudinal section, calculates its cross section maximum area (Smax), if simultaneously the several piece speckle is arranged, getting its maximum is observation index.Calculate speckle quantity (N).In addition, checked a hepatic and renal function in every month.
1.2.3 a situation arises to observe two groups of patient's cardiovascular and cerebrovascular vessel acute events such as angina pectoris, myocardial infarction, cerebrovascular accident and transient ischemic attack (TIA) etc.
([AKX-] ± S) represents that IMT, Tmax, Smax, N variation adopt t to check before and after two groups of treatments, and differences such as age, sex adopt the X2 check between two groups, and P<0.05 difference has significance 1.2.4 the statistical procedures data are with mean standard deviation.
Two groups of patients of 2 results do not find all that in treatment unusual and other fortuitous event of obvious hepatic and renal function withdraws from treatment, treatment group patient does not have the cardiovascular and cerebrovascular vessel acute events and takes place, matched group generation angina pectoris 3 times, take place TIA1 time, learn by statistics and handle, two groups acute cardiovascular and cerebrovascular vessel incident comparing difference notes take place: P<0.05 before and after the treatment of treatment group, there was no significant difference before and after each index treatment of matched group.
3 conclusions: atheromatous plaque, center are big and soft lipid cores, include cholesterol and cholesterol ester, cover thin fibrous cap on it, and collagen content is few, but a large amount of T lymphocytes, macrophage, the level and smooth endo cell of activated inner membrance are arranged.Wherein the minimizing of any composition all can cause dwindling of speckle volume.This group data observed result shows that medicine of the present invention can obviously dwindle the size of speckle, improves the thickness of middle film in the carotid artery.
In sum, medicine of the present invention is except improving by effect for reducing fat the carotid arterial atherosclerosis pathological changes, also by a series of non-lipid approach, as improve endothelial function, the reaction that reduces inflammation suppresses the increment of smooth muscle cell and macrophage etc., goes down or delays atherosclerosis.
Safety of medicine of the present invention, effective, better tolerance can be used as with the treatment of patient with carotid atherosclerosis and the routine administration of prevention cardiovascular and cerebrovascular vessel incident, have advantage safe and reliable, evident in efficacy, that side effect is little, cure rate is high.
(4) specific embodiment
Embodiment 1:
Get Herba Menthae 1g, Flos Chrysanthemi 1g, Rhizoma Cimicifugae 1g, Cortex Moutan 1g, Radix Et Rhizoma Rhei 1g, Radix Kansui 1g, Herba Andrographis 1g, Semen Plantaginis 1g, Caulis Akebiae 1g, Pericarpium Citri Reticulatae 2g, Rhizoma Osmundae 2g, Radix Scutellariae 4g, Concha Haliotidis 4g, Flos Carthami 4g, Radix Salviae Miltiorrhizae 4g, Pheretima 4g, Olibanum 4g, BIYUSAN 4g.Above medicament mixed decocting concentrates, and makes granule, every day 2-3 time, and each 1 gram, oral.
Embodiment 2:
Get Herba Menthae 2g, Flos Chrysanthemi 2g, Rhizoma Cimicifugae 2g, Cortex Moutan 2g, Radix Et Rhizoma Rhei 2g, Radix Kansui 2g, Herba Andrographis 2g, Semen Plantaginis 2g, Caulis Akebiae 2g, Pericarpium Citri Reticulatae 4g, Rhizoma Osmundae 4g, Radix Scutellariae 4g, Concha Haliotidis 4g, Flos Carthami 4g, Radix Salviae Miltiorrhizae 4g, Pheretima 4g, Olibanum 4g, BIYUSAN 4g.Above medicament mixed decocting concentrates, and makes water decoction according to a conventional method, and is every day 2-3 time, oral.
Embodiment 3:
Get Herba Menthae 1g, Flos Chrysanthemi 1g, Rhizoma Cimicifugae 1g, Cortex Moutan 1g, Radix Et Rhizoma Rhei 2g, Radix Kansui 2g, Herba Andrographis 2g, Semen Plantaginis 2g, Caulis Akebiae 2g, Pericarpium Citri Reticulatae 2g, Rhizoma Osmundae 4g, Radix Scutellariae 2g, Concha Haliotidis 3g, Flos Carthami 3g, Radix Salviae Miltiorrhizae 3g, Pheretima 3g, Olibanum 4g, BIYUSAN 2g.Above medicament mixed decocting concentrates, and makes capsule according to a conventional method, and is every day 2-3 time, each 2, oral.

Claims (1)

1. treat arteriosclerotic Chinese medicine composition for one kind, it is characterized in that: the raw material by following parts by weight is made:
Herba Menthae 1-2g, Flos Chrysanthemi 1-2g, Rhizoma Cimicifugae 1-2g, Cortex Moutan 1-2g, Radix Et Rhizoma Rhei 1-2g, Radix Kansui 1-2g, Herba Andrographis 1-2g, Semen Plantaginis 1-2g, Caulis Akebiae 1-2g, Pericarpium Citri Reticulatae 2-4g, Rhizoma Osmundae 2-4g, Radix Scutellariae 2-4g, Concha Haliotidis 2-4g, Flos Carthami 2-4g, Radix Salviae Miltiorrhizae 2-4g, Pheretima 2-4g, Olibanum 2-4g, BIYUSAN 2-4g.
CNA2008100169692A 2008-06-27 2008-06-27 Chinese medicinal composition for treating arteriosclerosis Pending CN101301384A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2008100169692A CN101301384A (en) 2008-06-27 2008-06-27 Chinese medicinal composition for treating arteriosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2008100169692A CN101301384A (en) 2008-06-27 2008-06-27 Chinese medicinal composition for treating arteriosclerosis

Publications (1)

Publication Number Publication Date
CN101301384A true CN101301384A (en) 2008-11-12

Family

ID=40111600

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100169692A Pending CN101301384A (en) 2008-06-27 2008-06-27 Chinese medicinal composition for treating arteriosclerosis

Country Status (1)

Country Link
CN (1) CN101301384A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620155A1 (en) * 2012-01-30 2013-07-31 Bionorica SE Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness
CN104394874A (en) * 2012-06-22 2015-03-04 国鼎生物科技股份有限公司 Methods and compositions for treating arteriosclerotic vascular diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620155A1 (en) * 2012-01-30 2013-07-31 Bionorica SE Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness
WO2013113772A1 (en) * 2012-01-30 2013-08-08 Bionorica Se Medication containing cimicifuga for use in the treatment of sarcopenia and myocardial insufficiency
CN104394874A (en) * 2012-06-22 2015-03-04 国鼎生物科技股份有限公司 Methods and compositions for treating arteriosclerotic vascular diseases

Similar Documents

Publication Publication Date Title
CN101507765B (en) Medicine for treating cerebrovascular disease and sequela thereof and preparation method thereof
CN116672377B (en) A Chinese medicinal composition for treating heart failure, preventing and treating asthenia and heart failure decompensation attack, and its preparation method
CN101342356B (en) Traditional Chinese medicine preparation for congestion retardarce, haemal tube obstruction and preparation method thereof
CN103041339B (en) Traditional Chinese medicine composition for curing migraine and preparation method thereof
CN115177669A (en) Traditional Chinese medicine composition with effect of treating myocardial bridge and application thereof
CN110327427A (en) It is a kind of to treat morning, the Chinese medicine composition of mid-term high blood pressure and preparation method
CN102512552B (en) Traditional Chinese medicine composition for treating exogenous fever
CN101301384A (en) Chinese medicinal composition for treating arteriosclerosis
CN101780140B (en) Drug for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN102441154A (en) Chinese medicinal preparation for treating gout
CN102343049B (en) Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity
CN103908490A (en) Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof
CN110292607B (en) Traditional Chinese medicine composition and preparation method for treating hypertension complicated with left ventricular hypertrophy
CN102579804B (en) Chinese medicine for treating stenocardia
CN102309561B (en) Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia
CN103099896B (en) Herb tea for treating cardiovascular and cerebrovascular diseases
CN104873689A (en) Chinese medicinal composition for treating cardiovascular diseases
CN102872191B (en) Channel dredging thrombolytic capsules and making technology
CN100546637C (en) A kind of traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof
CN1833699A (en) Quickly-acting antithrombotic and hemostatic medicine
CN105168653A (en) Traditional Chinese medicine composition used for treating coronary heart disease
CN106038812A (en) Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque
CN101396525B (en) Traditional Chinese medicine preparation for treating cerebrovascular disease
Gauthaman et al. Ischemic heart disease
CN105343358A (en) Traditional Chinese medicine capsules for treating coronary heart disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20081112